Key facts
- It has raised $9.5M; the latest was Early Stage VC in Aug 2024.
- Notable investors include Impact Assets, MedTech Innovator, National Institutes of Health, Catalytic Impact Foundation, Bird B. — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Starlight Cardiovascular
- ·The full record, as it builds
Funding rounds
No funding rounds for Starlight Cardiovascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Starlight Cardiovascular
Developer of a medical device intended to treat babies born with congenital heart disease. The company's devices are regenerative, infection resistant and have applications in cardiovascular patches, enabling healthcare professionals to improve the clinical outcomes of substitute conduit arteries in infants and children and reduce the risk of repetitive surgeries.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 8
- Website
- starlightcardio.com/
- Ownership
- Privately Held (backing)
Starlight Cardiovascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Starlight Cardiovascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Starlight Cardiovascular in its N-PORT filings yet. We sweep new filings monthly.